Zeblong T 80mg/8mg Tablet is a combination antihypertensive medication containing Telmisartan 80mg and Azelnidipine 8mg, indicated for the management of hypertension. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to effective blood pressure reduction. Azelnidipine, a long-acting dihydropyridine calcium channel blocker, exerts its antihypertensive effect by inhibiting calcium influx into vascular smooth muscle cells, resulting in vasodilation and decreased peripheral resistance. The synergistic action of these agents provides enhanced blood pressure control compared to monotherapy, improving cardiovascular outcomes and reducing the risk of stroke, myocardial infarction, and renal complications associated with hypertension. Zeblong T is typically administered once daily, with or without food, and dosage adjustments should be individualized based on patient response and tolerability. Common adverse effects may include dizziness, headache, peripheral edema, and fatigue. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated during pregnancy. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy. Zeblong T offers a convenient and effective option for patients requiring combination antihypertensive therapy.